Analyst Naz Rahman from Maxim Group reiterated a Buy rating on scPharmaceuticals and keeping the price target at $12.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors including scPharmaceuticals’ impressive financial performance and strategic initiatives. The company reported a significant increase in revenue for the second quarter of 2025, surpassing both consensus and internal estimates, which indicates strong market demand and effective sales strategies. Additionally, the launch of Furoscix for Chronic Kidney Disease (CKD) is progressing well, with early signs of success exceeding those of the initial heart failure launch.
Another factor contributing to the Buy rating is the anticipated positive impact of recent Medicare Part D changes and the potential benefits from the CMS Ambulatory Specialty Model proposal, which could further drive Furoscix’s growth. The upcoming submission of the sNDA for the auto-injector is expected to enhance gross margins significantly upon approval. Overall, the combination of these developments, along with narrowing net losses and projected breakeven by 2026, supports a positive outlook for scPharmaceuticals, justifying the Buy rating.
In another report released yesterday, Craig-Hallum also reiterated a Buy rating on the stock with a $12.00 price target.